An effective malaria vaccine may be available in 10 years or so, scientists hope.
Recent advances in biotechnology, including mapping the genome of the malaria parasite, point to a possible malaria vaccine.
If the big trials succeed, it could become the world's first malaria vaccine.
It took Glaxo 20 years to make significant progress with the malaria vaccine that failed to protect Ripley Ballou.
Some of what sub-Saharan Africa needs is new technology, like a malaria vaccine.
And an experimental malaria vaccine from GlaxoSmithkline is set to begin final-stage trials on thousands of African kids next year.
"The lack of an effective malaria vaccine is one of the biggest public health failures of our time, " Wolfe said.
If successful, that trial -- the largest malaria vaccine trial in Africa's history -- could lead to regulatory filing in 2011.
Some people have wondered whether a malaria vaccine is even possible.
FORBES: Glaxo's Billion Pill Giveaway And Its Malaria Vaccine
As part of a six-man experiment at the Walter Reed Army Institute of Research in 1987, he had himself injected four times with a genetically engineered malaria vaccine.
No individual country borrowing from the Fund or the World Bank will ever have the means or incentive to produce the global public good of a malaria vaccine.
Mr Gates said he believes a malaria vaccine is a few years away and there was a "good chance" that by 2015 a trial will have a successful completion.
Our initial partner in the mid-1980s was the U.S. Walter Reed Army Institute of Research, which needed a malaria vaccine to protect troops who might be deployed to malaria-endemic regions.
Glaxo's Stephenne hopes to sell huge quantities of malaria vaccine for a modest profit, while using its adjuvant components for more lucrative vaccines, such as one to prevent lung cancer recurrence.
Dr Xin-zhuan Su, one of the researchers, said the studies, which are published in the journal Nature, would change scientific thinking on the parasite and the development of a malaria vaccine.
But that lone success provided inspiration for a far more potent malaria vaccine that 20 years later is finally set to go into giant clinical trials next year at GlaxoSmithkline, where Ballou now works.
The malaria vaccine is far from perfect, protecting close to half of its recipients from the disease, but it is nevertheless a huge step forward in combating malaria across a continent that needs all the help it can get.
FORBES: Science and Skepticism: Malaria Vaccine Successful in Trial Run
Also, given the recent Lancet report on WHO's failure to provide effective malaria vaccine to the point of condemning some Africans to death just to save some money, makes the concern of the Nigerian clerics and other African governments very valid.
By knocking out a gene essential to the parasite's development, Kappe hopes to create a vaccine against malaria.
In a 2004 trial of 2, 000 children in Mozambique the Glaxo vaccine slashed severe malaria cases by about half.
As a group, PDPs like OneWorld Health, Medicines for Malaria Venture, the International AIDS Vaccine Initiative, Drugs for Neglected Diseases Initiative, and the Foundation for Innovative Diagnostics target diseases such as tuberculosis, malaria, Chagas, HIV and AIDS, and soil-transmitted helminthiasis, a group of parasitic infections caused by worms.
FORBES: Can Non-Profit Drug Companies Cure Diseases of Poverty?
Glaxo's malaria shot is at the forefront of a vaccine renaissance.
Cohen took the malaria surface protein used in Ballou's vaccine and fused it to a protein from the hepatitis B virus, creating a harmless particle that looked like a virus to the immune system.
The vaccine is designed to help complement existing malaria control measures, like mosquito nets, in Africa.
However, since natural immunity to malaria exists, researchers are reasonably optimistic that a vaccine, which stimulates this immunity artificially, should be feasible.
Malaria kills about one million African children a year and this vaccine can potentially save hundreds of thousands of lives, and avert billions of dollars in economic losses.
One study reported that the vaccine candidate was 53% effective in preventing episodes of clinical malaria in children five to 17 months old.
应用推荐